The OCMX™ is pleased to announce the listing of EMTensor Inc. to its online portal which offers Investors and Advisors the ability to learn more about this exciting opportunity.

FREMONT, CA, September 10, 2021 /24-7PressRelease/ — EMTensor is a Medical Device Start-up that was Founded 2012, Headquartered in Silicon Valley, CA, with a subsidiary in Vienna Austria. The company brings to market a Novel Full Wave Electromagnetic Tomographer that accelerates treatment of brain injury (stroke).

The company provides a brain imaging solution that is: hand portable, safe, fast and deployable closer to onset. They are publishing a proof-of-concept clinical trial at ESOC 2021: which validates the ability to distinguish hemorrhagic from ischemic stroke & to monitor treatment progress and efficacy.

The OCMX™ is pleased to announce the listing of EMTensor Inc. to its online portal which offers Investors and Advisors the ability to learn more about this exciting opportunity.

The OCMX™ has spent considerable time completing its due diligence on EMTensor Inc. and concluded that there is indeed a tremendous potential for this opportunity.

The OCMX™ noted that EMTensor Inc. exhibits the main components of any solid opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.


When time is brain… we buy you more!
• Dramatically lower SWaP$ (size, weight, power, $) – easy deployment closer to the stroke onset
• Image contrast promoting sensitivity to stroke and specificity to type, e.g. ischemic/hemorrhagic
• No ionizing radiation – no harm to patient
• Fast and frequent imaging – better outcomes

Adds use cases not currently possible:
• Bedside use = no queue. Similar to ultrasound
• Continuous monitoring improves treatment efficacy and provides early notification of recurrence
• Stroke detection at point of presentation to the healthcare system, at (or before) paramedics

EMTensors Brainscanner G4.1 and predecessors were used in an exploratory trial which just reported, and which will be published by our clinical partner at ESOC 2021. Brainscanner G4.1 is expected in 2022 to be productized as follows:
• Hardware and Software in production
• Several FDA approvals from the pipeline of submissions at ever increasing medical claim
• Deployed to multi-center clinical trials as proof of claims
• Develop a lucrative sales pipeline based upon well known medical claims that have never been delivered so early


Launching with a head scanner for stroke treatment acceleration, EMTensor will expand to other brain pathologies (e.g. tumor, aneurysm etc., perhaps even migraine, mental health issues), penetrating from hospital through to community deployment and a new market which is the stroke equivalent of the AED.

From there, EMTensor will expand to other body parts, ultimately the entire body and all ailments visible as blood disruption delivering on the true imaging vision of a universal utterly non-harmful screening tool that could appear in such places as dental offices, general practitioners, virtually any care facility and diagnose via cloud software agents the entirety of pathologies visible within the envelope of the data acquisition hardware instance – thereby ultimately disrupting the entire existing and harmful medical imaging market.


Stephen Pearce, CEO
Multi-industry professional CEO who has driven revenue growth above 100% year over year at all 8 prior companies in 3 years or less. Beginning with a PhD in Electromagnetics Stephen is especially skilled for EMTensor having launched RF phased array products almost every year of his career – brain scanner G4.1 being no exception.

Abraham Cohn, Chief Engineer
A systems engineering leader with over 20 years’ experience driving the advanced development funnel for $100M portfolio at a leading medical imaging strategic.

Ramiz Ballou Product and Operations Lead
Over 25 years’ experience driving growth at startups and large OEMs such as Nortel, Cisco, with a special talent for introducing Agile/Waterfall hybrid and quality management processes, managing contract manufacturers, channel partners and go to market.


The OCMX™ is changing how companies generate exposure in the financial marketplace and raise funds as we know it. The OCMX™ serves both public and private companies in need of market exposure during financial raises. It does this by way of connecting the relevant companies with financial institutions all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia.

The OCMX™ connects investors and advisors directly with companies seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors.

The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.

Contact Us
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
Tel: 1-866-209-6862
Email: [email protected]

EMTensor Inc. gets listed on THE OCMX™

For the original version of this press release, please visit here